About Aspira Women's Health
Aspira Women's Health is helping transform women’s health with the discovery, development, and utilization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. Our FDA-cleared products OVA1® and OVERA® detect the risk of ovarian malignancy in women with adnexal masses. Recently launched, Aspira GenetiXSM testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of experience in ovarian cancer risk assessment, Aspira Women's Health has expertise in cutting-edge research to inform our next generation of products. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection and optimize treatment plans.
Featured VideoView More
Aspira Women's Health Investor Presentation
Aspira Women's Health Investor Presentation August 2021 | Download
Investor Resources & Financial Information
Click a tab below to view more information
Below is a summary of our committee membership information.
|Audit Committee||Compensation Committee||Nomination and Corporate Governance Committee|
|James T. LaFrance (Board Chairperson)||Member||Member|
|Veronica G.H. Jordan, Ph.D.||Member||Chairperson|
Aspira Women's Health is followed by the analysts listed to the right. Please note that any opinions, estimates or forecasts regarding Aspira Women's Health’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Aspira Women's Health or its management. Aspira Women's Health does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
- William Blair & Company
- Cantor Fitzgerald
- Truist Securities, Inc
Webcasts and Presentations
Aspira Women’s Health, Inc. to Report Third Quarter 2021 Financial Results
Wednesday, November 10 at 8:30 am ET
Conference ID: 13724440
Aspira Women’s Health, Black Women's Health Imperative Lead Congressional Briefing
September 27, 2021